These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 28174424)

  • 1. Targeting A2 adenosine receptors in cancer.
    Allard D; Turcotte M; Stagg J
    Immunol Cell Biol; 2017 Apr; 95(4):333-339. PubMed ID: 28174424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.
    Kazemi MH; Raoofi Mohseni S; Hojjat-Farsangi M; Anvari E; Ghalamfarsa G; Mohammadi H; Jadidi-Niaragh F
    J Cell Physiol; 2018 Mar; 233(3):2032-2057. PubMed ID: 28233320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting adenosine and regulatory T cells in cancer immunotherapy.
    Churov A; Zhulai G
    Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
    Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
    Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
    [No Abstract]   [Full Text] [Related]  

  • 5. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
    Allard B; Longhi MS; Robson SC; Stagg J
    Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the adenosine pathway for cancer immunotherapy.
    Hammami A; Allard D; Allard B; Stagg J
    Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD73-adenosine: a next-generation target in immuno-oncology.
    Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
    Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting adenosinergic pathway and adenosine A
    Abouelkhair MA
    Med Hypotheses; 2020 Nov; 144():110012. PubMed ID: 32590324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD39 - A bright target for cancer immunotherapy.
    Guo S; Han F; Zhu W
    Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
    Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
    FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
    Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
    Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
    Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
    J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clustering of adenosine A
    Figueiredo AB; de Oliveira E Castro RA; Nogueira-Paiva NC; Moreira F; Gonçalves FQ; Soares RP; Castro-Borges W; Silva GG; Cunha RA; Gonçalves T; Afonso LCC
    FASEB J; 2021 May; 35(5):e21509. PubMed ID: 33813781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine and adenosine receptors in colorectal cancer.
    Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
    Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD73 on cancer-associated fibroblasts enhanced by the A
    Yu M; Guo G; Huang L; Deng L; Chang CS; Achyut BR; Canning M; Xu N; Arbab AS; Bollag RJ; Rodriguez PC; Mellor AL; Shi H; Munn DH; Cui Y
    Nat Commun; 2020 Jan; 11(1):515. PubMed ID: 31980601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
    Robert L; Ribas A; Hu-Lieskovan S
    Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.